SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug. But with the ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune ...

China has proved to be a fertile ground for innovation as evidenced by some big deals in the antibody-drug conjugate (ADC) space, and the number of candidates entering clinical trials in China or ...